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How ethics committees and requirements
are structuring health research
in the Philippines: a qualitative study
Gideon Lasco1,2,3, Vincen Gregory Yu1,3* and Lia Palileo‑Villanueva3

Abstract
Background: The last few decades have seen the rising global acknowledgment of the importance of ethics in
the conduct of health research. But research ethics committees or institutional review boards (IRBs) have also been
criticized for being barriers to research. This article examines the case of the Philippines, where little has been done to
interrogate the health research and IRB culture, and whose circumstances can serve as reflection points for other lowand middle-income countries.
Methods: Semi-structured interviews were conducted from July to October 2020 to elicit health researchers’
perspectives and experiences regarding IRBs and the ethics approval process in the country, as well as counterpoint
narratives from researchers who have also worked for IRBs.
Results: Across the fields of clinical, public health, and social science research, the issue of ethics review revealed
itself to be foremost an issue of inequity. IRB processes serve as a barrier for those outside the academe; those belong‑
ing to institutions, cities, or entire regions without their own accredited IRBs; and researchers working independently,
without ample budget, or on highly specialized topics—more so for non-clinical researchers who must grapple with
the primarily biomedical framework of most IRBs. Consequently, the research landscape invariably favors those with
the resources to do research, and researches that tend to attract funding.
Conclusion: The broader challenge of equity in health research will entail more fundamental reforms, but proximal
interventions can be done to make the ethics approval process more equitable, such as enhancing institutional
oversight, regulating IRB fees, and enabling a more supportive and welcoming environment for early-career, student,
independent, and non-clinical health researchers. This article ends by reflecting on the implications of our findings
toward the larger research culture.
Keywords: Research ethics committees, Institutional review boards, Research ethics, Health research, Research
inequity, Philippines
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Background
The past few decades have witnessed an increasing
acknowledgment of the importance of ethics in the conduct of human research. Consequently, professional
organizations and academic institutions around the
world have organized ethical guidelines and review committees (here on alternately referred to as ethics boards or
institutional review boards [IRBs]) to ensure researchers’
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adherence to ethical principles. As such, securing ethics
approval has become essential to the initiation, funding,
and publication of health research.
But IRB processes have also been criticized for being a
barrier to research. Examining two multi-center Australian researches, Barnett et al. found high costs—both in
terms of time and money—in obtaining ethics approval
[1]. Kendall and Halliday highlighted particular issues
faced by qualitative researchers, including the challenges posed by a “biomedical research ethics paradigm”
to researchers with “a social justice agenda.” [2] (p. 308)
Summarizing concerns raised by existing scholarship,
Nicholls et al. wrote:
While few would disagree with the general need for
ethics review, existing review processes are often
criticized; common complaints include the amount
of paperwork required, inconsistency of decisions
between review boards, and suggestions that ethics review systems may not be equipped to properly
review specific types of research [3].
Nicholls et al. further underscored the absence of
“gold standards against which to evaluate research ethics
review processes”; and, crucially for the Philippine context, how “there has been little in the way of published
research on the subject of assessment of research ethics review.” [3] In fact, a quick PubMed search, coupled
with our preliminary library research, revealed no studies
dealing with this topic in the Philippines.
Following the above and other researches, we set out
to examine the ethics approval process in the Philippines
according to these three questions:
1.
How are demands for ethical research structuring the health research landscape?;
2.
What are the experiences and particular challenges of Filipino health researchers with regards to
IRBs?; and
3.
How exactly do researchers from specific disciplines (e.g. clinical researchers versus social scientists) feel about ethics and IRBs?
Our study builds a preliminary knowledge base—and
not necessarily an exhaustive picture—for this particular
topic in the Philippines. Through qualitative interviews
that elicited the perspectives and experiences of Filipino researchers themselves, as well as people involved
in Philippine IRBs, this study charts the ethics approval
process in the country and identifies contemporary barriers and facilitators along the way. Building on this data,
we offer policy recommendations for academic institutions, IRBs, and government bodies that not only speak
to the situation of health research in the Philippines, but
are also relevant to other contexts, especially in low- and
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middle-income countries where researchers and institutions alike have likewise adapted to the demands of ethics
in research.
Ethics review in the Philippines

Relative to the Global North, the institutionalization of
research ethics processes in the Philippines is a fairly late
trend. In the late 1980s, for example, IRBs were already
present in over 60 percent of hospitals in the United
States [4]; while by 2000, “more than 95% of Portuguese
hospitals had established” an IRB [5] (p. 485).
In contrast, in the 1980s the Philippines was only seeing the formation of a National Ethics Committee, tasked
to “promote ethics review in health research.” [6] Within
that decade, the only major academic or research institution in the country with a self-run IRB was the Research
Institute for Tropical Medicine under the Department of
Health (DOH) [7]. By the early 2000s, “only 50 percent of
[Philippine] institutions [had] an [IRB].” [8] (p. 24).
In 2006, the Philippine Health Research Ethics Board
(PHREB) was officially established. Consisting of members from various research disciplines, the board’s
mandate includes overseeing the establishment and performance of IRBs in the country, as well as “[networking]
with relevant local, national and international organizations.” [9] As of January 2021, the PHREB website lists
104 accredited IRBs in the country, 40 of which are found
in the capital region of Metro Manila.
The country’s leading academic institutions established their own IRBs only within the last 15 years—for
example, in 2010 for the University of the Philippines
(UP) Manila, which houses the National Institutes of
Health and is widely considered the country’s premiere
health-sciences university [10]; and in 2015 for Ateneo de
Manila University [11]. For the social sciences, the country’s mother organization, the Philippine Social Science
Council, instituted its dedicated IRB only in 2017 [12].
Significantly, the Single Joint Research Ethics Board
(SJREB) was formed under the DOH in 2017. Tailored
specifically to ease the ethics approval process for multisited studies, the SJREB is the closest to a one-size-fitsall mechanism for multisited protocols in the country,
in that it furnishes such protocols with blanket approval
applicable to all hospitals under the DOH, allowing
researches to proceed with data gathering without needing to obtain separate approval for each site [13].

Methodology
From July to October 2020, we conducted semi-structured interviews with a total of 40 researchers in the
Philippines. Because of the coronavirus disease 2019
(COVID-19) pandemic, we had to conduct the study
remotely; at the time, our team members, all health
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researchers with experience in qualitative work, were
each based in a different part of the country. Heeding Mays and Pope’s [14] call for purposive, theoretically informed sampling, and drawing on what Marshall
describes as the “researchers’ practical knowledge of the
research area,” [15] (p. 523) we purposively recruited our
participants through peer referrals and targeted searches
via Google Scholar, keeping the list as inclusive as possible so long as the interviewee was relevant to the ethics
review process (e.g. as a researcher, board member, journal editor, government health official, hospital residency
training officer). However, navigating the ‘new normal’
of the pandemic, and the changes it imposed upon academia and research culture, meant that realistically we
had to simplify our participant selection and also consider the fact that our potential interviewees—all fellow researchers—were imaginably in similar straits with
regards to adjusting to the pandemic. As such, for ease of
access, we first approached individuals who were already
known to us (e.g. at work), either through phone call,
text message, or e-mail, before blindly contacting those
with whom we were completely unacquainted. Prior to
the interviews, our participants were sent the interview
guides for their perusal; this preliminary correspondence also served as an avenue for them to raise questions
about the study or concerns regarding their participation.
We initially categorized our participants according to three major disciplines: clinical research, public
health research, and social science research. IRB members constituted a fourth category, and key informants—ranging from journal editors, heads of private
research firms, to past and present government officials
in health- and research-related fields—constituted the
fifth. However, many participants did not necessarily belong to only one category, thus accounting for
the participant distribution according to discipline
exceeding the total number of actual participants. Save
for three participants—two from the Northern Mindanao region and one from Cavite province—all interviewees were based in Metro Manila. Nearly half were
affiliated with the UP system. Fifteen participants were
early-career researchers (including graduate students),
while the rest were considered established researchers. Data saturation became our determinant for the
final sample size: During data gathering, our team regularly consulted with one another regarding the findings
of an interview in order to determine whether we had
attained some form of data saturation in each category
of interviewees. Cognizant of our study’s aim to provide a preliminary—and not necessarily a definitive or
exhaustive—picture of our subject matter, we would
still encounter considerable saturation usually by the
10th interviewee, after which we would cap interviews
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for that category. In the end, our selection also considered a gender balance, workplace affiliation, and
research discipline, all summarized in Table 1.
Our remote interviews were conducted either
through phone call or video-conferencing software
like Zoom. This capability to participate in a remote
interview became our sole exclusion criterion. These
interviews usually took 30 to 45 min. Although the
interviews followed a general format—one that began
with the interviewee’s personal experiences (e.g. their
professional background, their individual experiences
in research and with IRBs) before transitioning to more
general topics like their views on ethical research,
IRB practices in the country, and the impact of IRBs
on research culture—we still tailored our questions
according to the participant’s background and therefore used four separate guides (see Additional file 1 for
the final interview guides). To reduce bias during the
interviews, given that our team members all had prior
interactions with IRBs, we strove as much as possible to
follow the interview guide, sticking to one open-ended
question at a time, and to remember that we were there
as interviewers only, and not co-generators of insight.
Our initial interviews served as pilot tests, but as we
conducted more interviews, we also adjusted and
tweaked specific questions that were inconspicuously
biased, as well as allowed the participant’s response to
shape succeeding or follow-up questions.
Consent forms were signed electronically; likewise, participant tokens were delivered via an online
medium. The audio copies of the interviews were sent
to transcribers who had signed nondisclosure agreements, and upon receiving the finished transcripts, our
research team proceeded to ensure participant anonymity by removing as much identifying information as
Table 1 Description of participant characteristics
Distribution according to gender
Male

21

Female

19

Distribution according to research discipline
Clinical research

13

Public health research

11

Social science research

14

IRB member

10

Key informant

5

Distribution according to affiliation
University of the Philippines system

17

Private universities or teaching hospitals

10

Nongovernment research firms

9

Others

4
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possible in each transcript. Only our research team has
access to all 40 transcripts, which have been secured in
a password-encrypted folder.
All transcripts were uploaded to a secure, offline
NVivo 10.0 database and approached by way of deductive thematic analysis. Guided by our literature review,
our research team first read the transcripts individually
to come up with initial codes. We consulted with our
team members regularly to ensure our individual readings of the text were devoid of researcher bias. Comparing codes led to our preliminary themes, after which we
did another round of reading to arrive at the final themes
by consensus. Our study was approved by the UP Manila
Research Ethics Board (UPMREB 2019–259-01).

Results
Across all three sectors of health research, researchers are
one in recognizing the importance of ethics in the conduct of their work. All our clinical researchers, for example, agreed that it is now safer than ever to conduct trials
precisely because IRBs exert rigid measures in evaluating
protocols. But such procedural rigidity has also been criticized, with one participant describing the whole application process as “intimidating.” In this section, we discuss
these criticisms and offer perspectives from researchers
who are also IRB members, with particular attention to
the differences among the three sectors.
Ethics review takes a long time

The researchers’ most common and prominent complaint is that the review process in the Philippines is
time-consuming. According to them, it takes anywhere
between two weeks to a month from the time of protocol submission before IRBs even give an initial decision,
and between two to three months before a final decision
can be reached. Accounting for protocol revisions and
resubmissions, the whole process can sometimes last
as long as “almost a year,” disrupting research timelines
even when a long process has been anticipated. A public
health researcher said a project she was involved in was
delayed for almost a year only because the protocol was
not approved immediately—despite zero requests for
revisions from the reviewers. Separately, a consultant at a
tertiary training hospital shared:
Our hospital was supposed to participate in an
international clinical trial. But it took a long time
for the ethics board to approve the study that by the
time we got approval, the trial was about to close.
We ended up withdrawing our participation.
As the latter quote suggests, the time-consuming
nature of the review process is of great concern particularly for researchers who are working on urgent studies
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or operating on a limited timeline. A head of a private
research firm counted at least three recent instances of
potential international collaborators backing out of a
Philippines-based study for this reason alone. Even nonprofessional settings experience similar constraints: A
university professor talked of instances when students
got delayed or had to drop out simply because their thesis proposals were not approved promptly. Consequently,
researchers are either forced to meticulously account for
the estimated review duration in structuring their studies—or altogether abandon certain aspects of proposed
projects, if not their entirety, that cannot afford longer
time frames.
Another impact is that, within the health research
community in the Philippines, certain IRBs have gained
reputations in terms of how fast they can process applications. Our participants spoke of knowing exactly which
boards have fast turnaround times and can be relied
upon to approve studies with limited timelines. One
researcher described an IRB based in a private hospital
as almost “machine-like” in its predictability to approve a
study swiftly, making it a favorite among those in a hurry
despite being “less prestigious” than university-based
boards.
Our participants did identify experiences with efficient
IRBs that can produce initial results within two weeks
and finish the whole process in a month. Some also said
the COVID-19 pandemic has forced IRBs to be more
efficient—for instance, by finally accepting email submissions and carrying out correspondences accordingly.
Nevertheless, on the whole, the researchers felt that IRBs
don’t expedite reviews as often as they should or provide
more manageable timelines.
Ethics review is costly

Regarding the financial aspect of applying for ethics
approval, most of our participants said that the cost is
usually not a problem—so long as the concerned study
has funding. That said, our interviews showed notable
variability in the rates that IRBs charge per application.
Some university boards, for example, completely waive
their fees for all student and faculty applications, while
others provide considerable discounts. On average, however, the fees range between PHP 20,000–50,000 (US$
416–1,040), and can go as steep as PHP 80,000 (US$
1,664) per application.
Even with funding, our participants admitted to being
concerned at how these rates eat up a considerable chunk
of the budget. But for independent and student researchers, the grim and obvious implication is that these fees
must come from their own pockets—leading one public
health researcher to speculate that the barrier inevitably imposed by these fees may not only be limiting the

Lasco et al. BMC Med Ethics

(2021) 22:85

country’s research landscape to certain circles where
funding is easily available (e.g. academe), but may also be
discouraging independent or starting researchers from
pursuing their work. That participant continued:
As head of [redacted private research firm], even I
find a fee of PHP 30,000 [US$ 624] exorbitant. But
I’ve also been approached by friends from abroad,
PhD students who want to do research in the Philippines, who are just shocked at how much our ethics
boards want to charge them.
Moreover, precisely because there is no rigid regulation
enforcing some semblance of uniformity upon IRB rates,
some participants were concerned that IRBs have been
taking advantage of this “financial opportunity,” as this
public health researcher illustrated:
The bill for ethics review can include two items. One
is the ‘ethics review fee’, which is manageable, say, at
around PHP 20,000 (US$ 416). But a lot of hospital boards add the second item, a so-called institutional fee—and that’s where it gets super arbitrary.
For a project that I did with an American government agency, for example, one of our hospital sites
charged us something close to PHP 100,000 [US$
2,081], which was way above what we could have
expected. When we asked for justification for the fee,
they couldn’t even provide one, which to us was code
for, ‘We know you have a lot of money, so cough it up’.
It’s ironic that so-called ethics boards engage in such
a gray area of practice.
As that excerpt shows, the apparent inconsistencies in
and unpredictability of these fees are worrying enough—
but more troubling is the idea that ethics review is fast
becoming a business. One social scientist said it best:
I’m convinced there is a market for ethics review—
that it can be a lucrative industry if you want to go
down that path. I mean, reviewers just have to read
a protocol, comment on it, eventually give a decision—and the board can earn something like PHP
50,000 [US$ 1,040] from it? And if they’re fast, it will
only take a month to do that, even less.
That, in fact, is precisely what a member of a private
hospital’s in-house board confided:
It’s easy to say that having their own in-house IRB
can position hospitals as prime movers and innovators when it comes to research. But an IRB is also
admittedly a huge source of funds. There is so much
money [to be earned from participating] in multicountry clinical drug trials. Coming from a privatehospital standpoint, I’d say that is one very compel-
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ling reason to form an IRB.
Ethics committees are concentrated in major cities

Aside from the time and cost, our participants also identified the concentration of IRBs in Metro Manila as a concern, particularly for researchers based in the provinces.
A clinical researcher from a major Northern Mindanao
city, for example, said that in her city, she “wouldn’t know
of any other ethics board to go to besides the one in my
hospital.” Likewise, a social scientist from a neighboring
town said that, as far as his field of research is concerned,
he always has to go “out of town” to get ethics approval.
Many researchers agreed that the SJREB has been
a welcome solution for multisited studies. But, as one
researcher from the DOH noted, this solution has its own
shortcomings: “One of the earlier challenges [encountered by SJREB] was resistance from the individual ethics review boards, who felt like they were surrendering
their power and feared they would not be paid anymore
individually.” Another public health researcher pointed
out a second shortcoming of this system: Since the
SJREB strictly applies only to hospitals under the DOH,
private institutions can refuse to recognize that blanket
approval and still require researchers to apply for separate approval under their own boards (as was this participant’s experience). “Instead of going through one board
[SJREB only], in the span of a year our team ended up
going through three [including two private institutions
that acted as described],” that participant said. Thus, up
to now, the need to obtain ethics approval remains a preliminary obstacle among those whose institutions—or
cities—do not have their own IRBs.
Ethics review is designed for clinical research

Non-clinical researchers highlighted a pressing concern
not shared by their clinical counterparts: Their perception that IRB processes have been designed with clinical research in mind—and therefore inappropriate for
non-clinical disciplines. Fundamentally, this clinical orientation manifests in the paperwork that IRBs require
researchers to accomplish. As a public health researcher
said:
It’s bad enough that [IRBs] that have yet to transition to digital require you to fill out a ton of paperwork. But many of those questions and forms are
actually irrelevant to non-clinical studies. It would
be more efficient for everyone if, for example, template forms were already designed according to specific types of studies.
This bias is also reflected in IRBs’ compositions—and
the kind of mindset and expertise, or lack thereof, that
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members consequently bring into their work. For example, one social scientist pointed out how hospital-based
IRBs are usually composed of clinicians—and therefore
cannot be expected to competently evaluate social
science researches... [Moreover,] it’s not just a matter
of board composition—a certain sector being overrepresented or underrepresented—but also a matter of lack of training. Boards in the Philippines just
aren’t as interdisciplinary as they ought to be.
As such, to quote a clinician who does mostly qualitative research:
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once refused to approve a thesis advisee’s proposal not on
ethical concerns, but on objections to the methodology:
It was an online survey with nothing particularly
sensitive about it—I should know because I had
already vetted it—so after all the back-and-forth
with the board, I put my foot down and sent them
a stern letter telling them to stop messing with our
methodology. They backed down and let the study
proceed as originally designed.
Ethics review for ethics review’s sake?

Ethics boards can disapprove or question protocols
not because they are ethically unsound, but because
they have subjective qualms over methodology—and
most of the time these qualms result from the simple fact that the board members are unfamiliar with
how that methodology works.

Taken together, the above complaints shape Filipino
researchers’ attitudes toward the ethics approval process—and influence decisions on which topics to do
research on, which IRBs to apply to, and whether to pursue a research idea in the first place. As one social scientist confessed:

What happens in such cases, a participant from a
firm that specializes in outsourced processing of hospital-based protocols said, is that IRBs then tend to act
in a reactionary manner. “They react to what you show
them rather than knowing the right questions to ask. I’ve
handled many studies with novel or unfamiliar data-collection tools that got questioned relentlessly over their
design alone.”
It is easy to see, then, where the complaints regarding IRBs overstepping their mandate or “meddling with
the study,” to use one participant’s words, are partly
rooted on—and why, when IRBs justify such ’overreach’
by saying that “a study cannot be ethically sound if it is
not methodologically or technically sound,” researchers
would not believe them. Across all three sectors, we had
participants who raised that exact point, identifying the
frequent overreach of authority on the part of IRBs as a
major cause of tension between researchers and boards.
This tension becomes more discernible as one deviates
farther from clinical research and is most pronounced in
the social sciences.
More than one social scientist experienced working
with a board that insisted on written informed consent
for non-clinical studies on vulnerable populations where
non-written consent has long been established as the
safer practice. In one such study, the board refused to
back down, giving the researcher no choice but to forego
the project. One researcher working on an ethnographic
study with indigenous peoples—a field where study populations are now recognized as co-generators and coowners of the data yielded during fieldwork—related the
difficulty of convincing an IRB that the biomedical norm
of destroying data after a certain time was not applicable in this case. A university professor shared how an IRB

It quickly becomes discouraging to do research in
the country because your mindset, as far as IRBs
are concerned, is that you will really have to fight to
get approval. I have had experiments in mind that
I’ve had to abandon over the mere thought that I
wouldn’t get approved.
Given how the ethics review landscape is only in its
relative infancy, the same participant continued, “the way
these boards are operating right now, it’s almost like they
think they’re at a dissertation defense and researchers are
there to defend their study.”
“Here in the Philippines it’s almost as if IRBs are dictating to researchers, treating them like they don’t know any
better,” said the head of a private research firm, going on
to say how
it becomes difficult to accept that kind of treatment
when you know these boards are not perfect themselves. The worst experience I’ve had was when a
study was returned to me after quite some time with
comments that had absolutely nothing to do with my
paper—because they were meant for another study.
Such experiences have led researchers to adopt a pragmatic view of ethics: as a necessary, if bureaucratic, step
in their projects. “We only look at two things,” a privatesector researcher said, “fast turnaround times and inexpensive costs.”
A public health researcher separately added that the
ethics review process is all about working toward an
approval, and the moment that approval is obtained, the
whole process abruptly comes to an end: There is usually no active follow-up from the IRBs during the course
of fieldwork and beyond, even as the requirements for
approval emphasize the necessity of such a process; in
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fact, most of the time, the burden of follow-up falls on
the researchers themselves, who end up actively updating
the boards regarding their progress. In this sense, ethics approval is reduced to a mere piece of paper, something to be obtained, rather than a thorough evaluation
of the conduct and impact of the study both from within
and without. In the end, that same researcher said, the
demands of IRB application processes take away time
that would have been better devoted to preparing for the
actual analysis, writing, and publication of a study.
In fact, some participants fear that ethics boards may
be fomenting a culture of gatekeeping insofar as research
is concerned, given their lack of accountability. Despite
the existence of PHREB, these researchers complain that
there is no feedback mechanism to air their concerns
regarding the approval process and no discernible metric
system to evaluate the performance of IRBs.
In many ways, all these criticisms are reflective not only
of IRB practices in the country, but of the larger research
landscape. Commenting on the inordinate amount of
time it takes IRBs to process applications, a participant
from a firm specializing in outsourced processing of hospital-based protocols said:
The perfect way to describe our research landscape is
that there is a lot of research waste going on, and it’s
all rooted in the lack of protected time for research.
I’ve seen how it is in other countries, where even junior researchers are really given protected time to do
research, where the whole system is very accessible.
Here, the fact that we don’t have such dedicated
time already affects the quality of writing in our protocols to begin with.
“Ethics should be ingrained in every researcher and
must go beyond the IRB,” said a social scientist. At the
very least, that same scientist said,
IRBs should place a certain level of trust on the
researchers they are working with or the technical
review boards who have separately screened the protocols... Right now, how IRBs are shaping the way we
do research is in the mode of ‘I’ll develop a research
protocol that will be so benign, it will be immediately approved by an ethics committee’, instead of
‘I will be making a protocol that will not affect the
lives, health, and well-being of my respondents’.
Those are two completely different things.
Counterpoint: perspectives of IRB members

From the standpoint of researchers who have worked
in or are currently members of IRBs, the logistical limitations of IRBs can be explained by the simple fact
that unlike other countries, the Philippines has yet to
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professionalize research ethics. One participant said one
of the birthing pains of “building a culture of research
ethics” is getting people to appreciate and participate in
research ethics, to serve as reviewers and panel members. A participant from the DOH observed how “most
hospitals have no actual budget dedicated to sustaining
an ethics board. That is why ethics boards become highly
dependent on the fees that they charge to, say, pay for the
office space, the secretariat and administrative staff, etc.”
As a clinician-researcher put it:
The operation of IRBs is governed by a lot of privacy
and confidentiality. But even in big universities,
we are not always assured of lockable cabinets. We
should not be sharing a fax machine with another
office. We should have our own shredder.
Protracted turnaround times can be easily explained by
the fact that IRBs are often understaffed and swamped
with protocols. Almost always, IRB members also have
other responsibilities, such as being university professors or clinicians, and cannot devote all of their working
time to just evaluating protocols. Almost always, as well,
the compensation for IRB members is hardly commensurate to the amount of time and effort that they devote to
the work. One participant described present conditions
succinctly:
Reviewers are asked to read 300-page protocols and
paid for only an hour of the job. So you really have
to question why, in a clinical trial, for example, an
IRB would charge PHP 60,000–70,000 [US$ 1,250–
1,455] for review but pay its reviewers only PHP
1,000–2,000 [US$ 20–42] per protocol reviewed.
Where the perspectives of IRB members diverge from
our other participants is in the mandate of an IRB. “Many
researchers cling to this belief that ethics boards are barriers to research,” said one board member. “Researchers tend to become preoccupied with the science of
their protocols and end up ignoring the ethics of their
protocols.”
According to this subset of participants, a lot of the
back-and-forth that researchers complain about in their
dealings with IRBs has to do with the simple fact that
these protocols tend to be badly written. Researchers can
overlook the major, complicated issues such as the study
design, but, as one participant noted, the oversight can
be far simpler: “I have received studies that, in the objectives, stated the intent to compare this and that, but this
intent to compare is not even reflected at all in the study
design.”
They also emphasize that the existence of technical
review boards is not an excuse for IRBs to be less strict.
According to one participant,
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preliminary technical review is helpful, but in my
experience, most of the time it pays for me as an
ethics reviewer to also assess the technical aspects
simply because the technical review can miss out
on a lot of things that then make the study ethically
unsound.
Ideally, that participant continued, if the finances and
manpower can make it possible, only one committee
should do both ethical and technical reviews to streamline the whole process. In the end, another participant
said,
researchers don’t realize that when an IRB ‘oversteps’ and points out technical issues, it’s not because
of overreach or a matter of gatekeeping. It’s because
as an IRB member, you realize that the study goes
beyond the researcher; it will affect individuals and
communities.
A social scientist belonging to an IRB provided this
illustrative summary to the argument:
Let’s say you are doing a study on the impact of
COVID to mental health. If you settle for 400 as
your study population, imagine asking 400 people
these intrusive questions that would only magnify
the risks that they may have already been exposed
to. Inserting ethics into the question makes you ask,
for example, whether you can achieve the same
results with half the population size. It makes you
think about the responsibilities of a researcher, so
before you submit your protocol for approval, you
are already considering the soundness of the design
and other questions that you would have otherwise
ignored if you were solely focused on the science.

Discussion
An issue of inequity

On the whole, our study resonates with the global literature that have examined—and/or have been critical
of—the role, culture, and practices of research ethics
committees, beginning with an acknowledgment of their
necessity: Faced with the prospect of ethical review, most
of our participants echoed Schrag’s observation, in that
their first instinct is generally one of “eager cooperation.”
[16] (p. 122)
But as our findings also showed, the rift between
the perspectives of researchers and IRBs regarding the
review process transcends mere diverging views on what
constitutes “ethical research.” And in any case, the problems raised by Filipino researchers regarding that process
are only part of the continuum of ongoing debates worldwide—from the time-consuming and paperwork-heavy
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nature of ethics approval described by Gold and Dewa
[17] in their study of multisited researches; imbalances
in board composition that, as Schuppli and Fraser [18]
wrote, render evaluations ineffective; and the highly clinical framework of current review processes that Flicker
et al. have criticized for possibly doing more harm than
good and “placing communities at risk” through an
insistence on inappropriate measures of evaluation, particularly as imposed upon the social sciences and participatory research [19]. To go by Abbott and Grady, the
Philippine situation is similarly riddled with all forms of
inefficiencies and inconsistencies, be it in terms of application fees, duration of review, or outcomes of evaluations [20]. Additionally, although our limited findings
disallow us from fully arriving at the same, incontrovertible conclusion, the anecdotes of our participants regarding commercial IRBs nonetheless find some measure of
resonance in Lemmens and Freedman [21], who, a full
two decades earlier, already voiced concerns regarding
profit-related conflicts of interests as regards the operation of these ethics boards, and how these conflicts may
eventually compromise the quality of review and erode
public trust in IRBs.
In its most fundamental sense, then, ethics review is
an issue of inequity. The existing system serves as yet
another barrier for those outside the academe; those
belonging to institutions, cities, or entire regions without their own accredited IRBs; and researchers working
independently, without ample budget, or on highly specialized topics. And even for researchers affiliated with
institutions that have their own IRBs, the balance invariably tips toward those with sufficient funding and/or
those working on topics that tend to receive funding. All
of these contribute to the rise of what Patterson [22] calls
“spaces of marginalization” that privilege certain types
of research, and research topics—and eventually, knowledge production—over others.
As our own research demonstrates, non-clinical
researchers find themselves at the marginal end of that
divide. For these researchers, the inequitable landscape is
also one where they must abide by what Schrag describes
as “silly restrictions” that are inapplicable to their respective fields, and which are imposed mostly by IRBs that
lack the expertise to properly evaluate protocols and end
up applying “inappropriate” principles to such evaluations [16]. Often, IRBs operating on a highly biomedical
framework have exaggerated “protectionist concerns,”
[23] (p. 483) the imposition of which do not necessarily
result in more ethical research practices [24]. Instead,
in such a landscape, current guidelines may only serve
to actually “[impede] ethically sound or potentially beneficial research,” [25] (p. 161) and may be entirely unable
to address more complex, field-related situations already
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raised by existing scholarship [26]—further straining
researcher-IRB relations and aggravating researchers’
feelings of mistrust, if not outright antagonism [27, 28].
At worst, this “unquestioning transposition of ethical
principles from [clinical to non-clinical] research [may]
lead to inappropriate practices that… actually encourage
less ethical practice.” [24] (pp. 94–95).
Ultimately the demands that the ethics application process imposes upon researchers cannot simply be reduced
to discrete complaints—on matters of time, or finances,
or geographical proximity, or expertise from the side
of IRBs; it is an interplay of these factors that breeds an
environment that favors those with the resources to do
research—and those with researches that are more likely
to attract funding. In this manner, indeed, the ethics
review process becomes a matter of (in)equity.
Recommendations

While the broader challenge of equity in health research
will entail more fundamental reforms (as detailed by
Pratt, Merritt and Hyder [29]), more proximal interventions can be done to improve the research ethics process
and make it more equitable. For instance, an oversight
committee—in the case of the Philippines, PHREB—
should take a more proactive role in mediating the
debates of research culture, and go far and beyond its
mandate to promote the proliferation and evaluate the
performance of IRBs—with special emphasis on what
Coleman and Bouësseau [30] term outcomes assessment, or ensuring from the IRBs’ end that so-called ethical research actually carries on to the field. This is not to
undermine the trust between researchers and IRBs once
a research has been approved, but to say that IRBs that
require researchers to submit regular updates during data
gathering, for example, should also be more proactive
in seeking those updates or tackling unforeseen ethical
dilemmas that may arise after protocol review. Else, what
persists is the image of ethics approval as the ‘golden calf ’
of the research process, a mere objective to be attained
and surmounted.
Moreover, such a committee could also act as a
mediator in the financial burden of ethics review—for
example, by regulating and imposing uniformity on
fees—thereby potentially eliminating conflicts of interest
where money and/or power relations is concerned, making ethics approval more equitable while still allowing
IRBs a comfortable measure of financial self-sufficiency
(see, for example, the arguments of Emanuel, Lemmens
and Elliot [31]). That the complaints of our participants
who have worked or are part of IRBs centered mostly
around the lack of material support (in terms of personnel, office resources, and/or protected, compensated time
for IRB-related duties) only makes this kind of financial
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self-sufficiency an imperative—and all the more so when
one considers how this problem has been perennially recognized across global literature [20, 32].
For researchers, the institutions they represent, and
IRBs, the spirit of equity should extend to supporting
research topics that have not enjoyed as much scholarly
attention and making the landscape more hospitable
for early-career, student, and independent researchers.
To paraphrase Chatfield et al. [33], making this possible includes ensuring that IRBs are staffed with the
right kind of ‘qualified experts’—given that there are “no
absolute standards upon which IRBs can rely [in evaluating protocols]” and ethics boards must therefore bank
on “a fair exercise of intelligence and discretion on the
part of [their] members” [21] (p. 562)—and lessening the
bureaucratic roadblocks that make even getting ethics
approval already a laborious process. To recapitulate a
point made earlier, a change in research culture requires
not taking time away from the actual conduct of the
study—from data gathering, analysis, and paper writing.
In other words, fostering “a culture of ethics” instead of
“a culture of red tape,” to quote Burris and Welsh in Coleman and Bouësseau [30] (p. 4).
Doing so eventually boils down to the kind of larger
research culture that we foster, where: (1) research is
seen as an integral part of knowledge production, in
the academe as in other fields of society, and therefore
granted protected time and sufficient funding; (2) IRBs
are seen as instrumental partners in research and therefore granted sufficient human, material, and financial
resources to fulfill their mandate; (3) “ethical research” is
not viewed as culminating in IRB approval, but as foundational to research—and practiced deliberately, from the
writing of the study protocol to the final study analysis;
and (4) a certain level of ‘trust’ is established between
researchers and IRBs [34, 35], manifesting not through
what Makhoul [36] aptly labels “policing,” but through
a “collaborative and supportive relationship” that makes
‘allies’ out of IRBs and researchers [32].

Conclusion
Our study has certain limitations. First of all, our limited sample size means that our findings cannot be
interpreted as unequivocal generalizations of the health
research landscape in the Philippines, or even as definitive pictures of each sub-field of health research as far
as IRBs are concerned. Moreover, almost all of our participants hailed from Metro Manila, making it impossible to account for specific experiences in the country’s
many other cities and regions, given the variability in
academic and research culture across the nation. Our
participants’ affiliations were likewise limiting: We had
no interviewees who were undergraduate students,
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for instance, and nearly half of our participants were
affiliated with the state-funded UP system—a fact that
would have no doubt colored our participants’ careers
and narratives. The focus of our study itself—IRBs in
the context of health research—disallows our findings
from being considered as entirely valid conclusions
for other fields of academic, and even non-academic,
research in the country. As such, future avenues for
research may include IRB culture and practices in nonhealth research, as well as the relative infancy of multisited common review in the country.
Nevertheless, our study shows how the case of the
Philippines can serve as a point of reflection for similar low- and middle-income countries where research
inequities have persisted. The narratives of our participants show how, despite growing recognition of
the fundamental role of IRBs to research ethics, the
research landscape remains one that is riddled with
structural biases and deficiencies—problems that are
challenging to overcome, but which are definitely not
without solutions. Arguing that ethics review is essential even for non-medical research, Lindoff [37] calls
for opening up lines of dialogue between researchers
and IRBs, highlighting the importance of such partnership between the two parties. To this, we concur—but
with the caveat that such a partnership may flourish
only when the ethics approval process ceases to be a
barrier for researchers. Should a middle ground exist,
it should be one where researchers need not surmount
numerous structural inequities even before a study
has commenced; one where researchers don’t have to
“fight” for ethics approval.
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